mri/mrs biomarkers robert e. lenkinski, ph.d
TRANSCRIPT
![Page 1: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/1.jpg)
MRI/MRS Biomarkers
Robert E. Lenkinski, Ph.D.
http://catalyst.harvard.edu
![Page 2: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/2.jpg)
2
The major focus will be on non-neuro applications
• Issues-quantitation, relationship to physiology, metabolism
• Examples-DCEMRI, ASL, DWI, MRS
![Page 3: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/3.jpg)
Issues
• Quantitation-accuracy, precision, detection limits
• Standardization-acquisition, processing/analysis
• Validation
ADNI, NIHPD, OAI, RSNA-QIBA, ACRIN3
![Page 4: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/4.jpg)
Ashton, JMRI 31:279-288 (2010)
4
![Page 5: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/5.jpg)
5
http://www.adni-info.org/
✖✖
✖RF Pulse
Signal
![Page 6: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/6.jpg)
6
http://www.adni-info.org/
![Page 7: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/7.jpg)
7
![Page 8: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/8.jpg)
8
![Page 9: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/9.jpg)
9
![Page 10: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/10.jpg)
https://nihpd.crbs.ucsd.edu/nihpd/info/data_access.html
10
![Page 11: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/11.jpg)
https://nihpd.crbs.ucsd.edu/nihpd/info/data_access.html
11
![Page 12: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/12.jpg)
https://nihpd.crbs.ucsd.edu/nihpd/info/data_access.html
12
![Page 13: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/13.jpg)
Contrast Enhanced MRI of Has Contrast Enhanced MRI of Has Diagnostic Value in OncologyDiagnostic Value in OncologyBreast, Lung, Prostate, etc.Breast, Lung, Prostate, etc.
![Page 14: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/14.jpg)
![Page 15: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/15.jpg)
Behavior of Contrast Agent in the Body
B O D Y
Injection of
Contrast Agent
Kidney
Depends on: Cellular density or “Extracellular Volume Fraction” Blood vessel permeability “Microvascular Permeability”
Blood Stream
![Page 16: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/16.jpg)
Dynamic Contrast Enhanced MRI (DCEMRI)
Components– “High-field” MRI machine
(1.0 tesla or greater)
– Phased array torso coil
– Gadolinium contrast agent (GdDTPA)
– Images taken at several time points (spatial vs temporal resolution
– Software algorithm processes data for either parametric maps or semi-quantitative plots
![Page 17: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/17.jpg)
![Page 18: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/18.jpg)
18
Juergen F. Schaefer, Joachim Vollmar, Fritz Schick, Reinhard Vonthein, Marcus D. Seemann, Herrmann Aebert, Rainer Dierkesmann, Godehard Friedel, and Claus D. Claussen
Solitary Pulmonary Nodules: Dynamic Contrast-enhanced MR Imaging—Perfusion Differences in Malignant and Benign Lesions
Radiology August 2004 232:544-553;
![Page 19: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/19.jpg)
Fourteen malignant and no benign nodules demonstrated curve type A, demonstrating a fast initial SI increase and a marked decrease after 20 or 30 seconds. No SI decrease after the first bolus transit is present in curve type B, which was demonstrated by 18 nodules (12 malignant and six benign nodules). A more continuous SI increase without any sharp early peak after the first bolus transit demonstrates that curve type C was found in 14 nodules (one malignant and 13 benign nodules). Note that ultimately, the curves demonstrate a plateau. No relevant enhancement was calculated for the five benign nodules with curve type D.
14M-0B 12M-6B
1M-13B 0M-5B
![Page 20: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/20.jpg)
56yo w/ ↑ PSA (now 27.7)repeat –bx x3; 63 cores prior to MRI
20
T2-W
DCEMRI color map
pT2c Gleason 4+3
![Page 21: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/21.jpg)
Tofts Model Equation
SI= [a1*(e (-ktrans*t/ve)-e (-m1*t))/(m1-ktrans/ve)+
a2*(e(-ktrans*t/ve)-e (-m2*t))/(m2-ktrans/ve)+
a1*e (-m1*t)+a2*e (-m2*t)]*d*ktrans
Two Compartment Model
Negligble vascular space
Idealized arterial input function
)SI linear with Gd Agent Concentration(
21
![Page 22: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/22.jpg)
Challenges/Issues
How accurate is the model?
How precise are the values of Ktrans and Ve?
What is the influence of SNR and temporal resolution?
22
![Page 23: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/23.jpg)
• Modified ADNI/IRAT phantom for DCE-MRI• Defined generic DCE-MRI acquisition protocols• Conduct multi-center phantom reproducibility
study• Define procedure for routine phantom use• Develop simulated data set for algorithm testing
RSNA QIBA DCE-MRI Technical Committee
![Page 24: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/24.jpg)
http://www.rsna.org/research/qiba.cfm
24
![Page 25: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/25.jpg)
25
![Page 26: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/26.jpg)
http://www.rsna.org/research/qiba.cfm
26
![Page 27: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/27.jpg)
27
![Page 28: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/28.jpg)
Anatomic T2W and T1W early subtraction images and parametric maps for rBV and Ktrans at baseline and following 2 cycles of neoadjuvant chemotherapy in a clinically and
pathologically (A) responding patient and (B) nonresponding patient.
Ah-See M W et al. Clin Cancer Res 2008;14:6580-6589
©2008 by American Association for Cancer Research
![Page 29: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/29.jpg)
Change in MRI-derived tumor size and DCE-MRI kinetic parameters according to (A) clinical tumor response and (B) pathologic tumor response.
Ah-See M W et al. Clin Cancer Res 2008;14:6580-6589
©2008 by American Association for Cancer Research
![Page 30: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/30.jpg)
ASL Subtraction ExperimentControl Image Labeled Image
Imaged Slice
InversionLabeling
![Page 31: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/31.jpg)
Background Suppression is Enabling for Abdominal ASL
Control Label Difference
![Page 32: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/32.jpg)
DAY 0
DAY 8
sorafenib + bevacizumab
![Page 33: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/33.jpg)
Early changes at 1 mo in blood flow and tumor size compared with tumor size changes at 4 mo with a Spearman rank order correlation.
de Bazelaire C et al. Clin Cancer Res 2008;14:5548-5554
©2008 by American Association for Cancer Research
![Page 34: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/34.jpg)
Early changes at 1 mo in blood flow and tumor size compared with delay of progression of the disease after initiation of the treatment.
de Bazelaire C et al. Clin Cancer Res 2008;14:5548-5554
©2008 by American Association for Cancer Research
![Page 35: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/35.jpg)
Beth Israel Deaconess Med. Ctr.Weiying Dai, PhDPhilip Robson, PhDCedric de Bazelaire, MDGuillaume Duhamel, PhDDairon Garcia MSBarbara Appignani, MD Michael Atkins, MDTamara Fong, MD PhDDaniel George MDDavid Hackney, MDIgor Koralnik, MDBarbara Klemm, RNIvan Pedrosa, MD Daniel Press, MDNeil Rofsky, MD
AcknowledgmentsGottfried Schlaug, MDMagdy Selim, MDEric T. Wong, MD
University of PennsylvaniaJohn Detre, MDJiongjiong Wang, MD
GE Global Applied Sciences LabAnanth Madhuranthakam, PhDAjit Shankaranarayanan, PhD
Stanford UniversityGreg Zaharchuk, MD PhD
![Page 36: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/36.jpg)
36
![Page 37: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/37.jpg)
37
Gradient
time
![Page 38: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/38.jpg)
38
![Page 39: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/39.jpg)
39
![Page 40: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/40.jpg)
40
![Page 41: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/41.jpg)
functional Diffusion Maps (fDM)
• ADC maps from pre and post treatment are aligned
• Voxel-wise statistical analysis highlights the voxels with significant change over time
Results only for brain and animals models
Abdomen application: Non-rigid registration will introduce the registration error into the fDM computation
Image from: Hamstra et al, Proc Natl Acad Sci U S A, 2005
![Page 42: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/42.jpg)
![Page 43: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/43.jpg)
Our approach
• NdH/dT: Normalized cumulative histogram difference over time– Difference between the Cumulative histograms of the tumor ADC
values
– Area Under the Curve (AUC) represent the overall change in tumor diffusivity
– Normalization by the AUC of healthy tissue sample produce absolute global measure
Single number Intuitive to interpret No non-rigid registration is required Capture tumor heterogeneity
![Page 44: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/44.jpg)
NdH/dT: Representative examples
![Page 45: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/45.jpg)
RESONANCE ASSIGNMENTS
SUPPRESSED
X 30
UNSUPPRESSED
X 1
SUPPRESSED
X 525
X 1500
Cho
H20 Fat
Cho
H20
Fat
H20
-CH2-
Cho-CH3-
-(CH2)n-
-C=C-
![Page 46: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/46.jpg)
Journal of the National Cancer Institute, Vol. 94, No. 16, 1197-1203, August 21, 2002© 2002 Oxford University Press
------------------------------------------------------------------------
REVIEW
Clinical Utility of Proton Magnetic Resonance Spectroscopy in Characterizing Breast Lesions
Rachel Katz-Brull, Philip T. Lavin, Robert E. Lenkinski
![Page 47: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/47.jpg)
![Page 48: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/48.jpg)
![Page 49: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/49.jpg)
![Page 50: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/50.jpg)
Copyright ©Radiological Society of North America, 2004
Meisamy, S. et al. Radiology 2004;233:424-431
Figure 2
![Page 51: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/51.jpg)
Copyright ©Radiological Society of North America, 2004
Meisamy, S. et al. Radiology 2004;233:424-431
Figure 5
![Page 52: MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D](https://reader036.vdocument.in/reader036/viewer/2022062801/56649e265503460f94b159b4/html5/thumbnails/52.jpg)
MRI/MRS is ComplicatedNavigating through the maze to reach quantitation requires a systematic approach
52